IPSC
Century Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$413.01M
P/E Ratio
—
EPS
$-0.14
Beta
1.56
52W High
$3.04
52W Low
$0.43
50-Day MA
$2.32
200-Day MA
$1.24
Dividend Yield
—
Profit Margin
-8.78%
Forward P/E
—
PEG Ratio
—
About Century Therapeutics Inc
Century Therapeutics Inc. (Ticker: IPSC) is an innovative biotechnology firm at the forefront of advancing allogenic cell therapies aimed at transforming cancer treatment. Utilizing its proprietary induced pluripotent stem cell (iPSC) technology, the company is committed to developing novel off-the-shelf therapeutic solutions that enhance patient outcomes and broaden accessibility. With a robust pipeline of clinical-stage product candidates and strategic partnerships that bolster its competitive edge, Century Therapeutics is strategically positioned to lead advancements in the burgeoning cell therapy market, offering strong potential for clinical successes and favorable returns for investors.
Fundamentals
| Revenue (TTM) | $109.16M |
| Gross Profit (TTM) | $13.50M |
| EBITDA | $-1.94M |
| Operating Margin | -13.80% |
| Return on Equity | -5.98% |
| Return on Assets | -3.26% |
| Revenue/Share (TTM) | $1.26 |
| Book Value | $1.82 |
| Price-to-Book | 2.64 |
| Price-to-Sales (TTM) | 3.78 |
| EV/Revenue | 3.176 |
| EV/EBITDA | 133.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $180.35M |
| Float | $97.69M |
| % Insiders | 12.08% |
| % Institutions | 63.43% |
Historical Volatility
HV 10-Day
60.20%
HV 20-Day
75.31%
HV 30-Day
76.35%
HV 60-Day
85.00%
HV Rank
50.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($3.67 target)
1
Strong Buy1
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/5/2026